The National Health Service will begin its autumn Covid vaccine program next week, a month earlier than planned in response to the spread of a new variant
dubbed Pirola. Covid vaccines will be administered to care home residents and housebound individuals from Monday onwards, while over-65s and other vulnerable
groups will receive their appointments the week after.
On Aug. 30, NHS England shifted the autumn vaccination drive to start on September 11 in response to the new Covid-19 variant, BA.2.86, detected on August 18.
The primary groups can book through a national system upon receiving an invitation from the NHS. Some people may get an earlier call from their GP, and a few have
already scheduled Covid vaccinations alongside their flu jabs.
The NHS will begin inviting other eligible groups from Sept. 18. However, it is important to note that not everyone will receive a call at the same time. These
groups will include individuals aged 65 and over, those aged six months to 64 years in a clinical risk category, frontline health and social care workers, and
individuals aged 12 to 64 who are carers or household contacts of those with immunosuppression.
Two new subvariants of Omicron - BA.4 and BA.5 - are spreading much faster than other corovanirus variants in Europe, which could lead to more hospitalisations
and deaths as they become dominant, the EU's disease prevention agency said on Monday (June 13).
Most EU countries have so far detected low rates of the two subgroups. But in countries where the proportion has risen - such as Portugal, where BA.5 accounted for
87 per cent of cases by May 30 - there have been surges in overall cases, according to the European Centre for Disease Prevention and Control (ECDC).
The two sublineages were added to the World Health Organization's monitoring list in March and have also been designated as variants of concern by the ECDC.
Variants BA.4 and BA.5 do not appear to carry a higher risk of severe disease than other forms of Omicron.But an increase in case numbers from higher transmission
rates risks leading to an increase in hospitalisations and deaths, the agency said.
"The growth advantage reported for BA.4 and BA.5 suggest that these variants will become dominant," ECDC said in a statement on its website.
French drugmaker Sanofi said on Monday (June 13) an upgraded version of the Covid-19 vaccine candidate it is developing with GSK showed potential in two
trials to protect against the virus's main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.
While the two companies' first experimental Covid shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that
is moulded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.
Sanofi said this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants
who had an initial course of mRNA vaccines, a type made by BioNTech-Pfizer and Moderna.
In a separate trial conducted by a French hospitals network, Sanofi's Beta-adapted booster shot triggered a higher immune response than Sanofi's first-generation
shot or Pfizer-BioNTech's established vaccine in previously vaccinated volunteers.
The prevalence of Covid-19 infections in England rose to around one in 60 people in the week ending November 27, the Office for National Statistics said today (December 03), led higher by the dominant Delta variant rather than the newly identified Omicron.
The prevalence was up from one in 65 reported the previous week, the ONS said, adding that 99 per cent of all coronavirus infections which were sequenced were
genetically compatible with the Delta variant.
"To date, we have not identified any infections compatible with the new Omicron variant (B.1.1.529) among our survey participants," the ONS said.
Prime Minister Boris Johnson has introduced travel restrictions and some mask mandates, with a view to slowing the spread of Omicron while work is undertaken to
understand it better.
There have been 42 confirmed cases of the variant in Britain, which has mutations consistent with reduced vaccine efficacy.
Lapses in strategies to tackle COVID-19 this year continue to create the perfect conditions for a deadly new variant to emerge, as parts of China witness a
rise in infections, the head of the World Health Organization said on Friday (December 2).
The comments by WHO Director-General Tedros Adhanom Ghebreyesus mark a change in tone just months after he said that the world has never been in a better position
to end the pandemic.
"We are much closer to being able to say that the emergency phase of the pandemic is over, but we're not there yet," Tedros said on Friday.
The global health agency estimates that about 90% of the world's population now has some level of immunity to SARS-COV-2 either due to prior infection or vaccination.
"Gaps in testing … and vaccination are continuing to create the perfect conditions for a new variant of concern to emerge that could cause significant mortality,"
Tedros said.
COVID-19 infections are at record highs in China and have started to rise in parts of Britain after months of decline.
British drugmaker GSK said on Tuesday (December 7) its antibody-based Covid-19 therapy with US partner Vir Biotechnology is effective against all mutations of the new Omicron coronavirus variant, citing new data from early-stage studies.
The data, yet to be published in a peer-reviewed medical journal, shows that the companies' treatment, sotrovimab, is effective against all 37 identified mutations to date in the spike protein, GSK said in a statement.
Last week, another pre-clinical data showed that the drug had worked against key mutations of the Omicron variant. Sotrovimab is designed to latch on to the spike
protein on the surface of the coronavirus, but Omicron has been found to have an unusually high number of mutations on that protein.
"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO," GSK chief scientific officer Hal Barron said.
GlaxoSmithKline and Sanofi said on Wednesday (December 15) they expect data from late-stage clinical trials of its booster dose of their Covid-19 vaccine candidate in the first quarter, instead of this year, another delay for the potential shot.
The news came as two companies said preliminary data from trials showed the single-dose booster provided strong immune responses. They added that they need more
time to test the booster on more people who have not been infected by the virus before they can submit data to regulators.
The Phase III trial for the recombinant adjuvanted Covid-19 vaccine recruited most participants in the third quarter, coinciding with a significant increase in the number of people infected globally due to the Delta variant, it said.
"To provide the necessary data to regulatory authorities for the booster vaccine submission, the trial will continue to accrue the number of events needed for analysis, with results expected in Q1, 2022."
No safety concerns were identified.
This is the latest delay for the vaccine's development, putting the companies further behind rivals in the race for Covid-19 shots.
Britain will offer a Covid-19 booster shot to all adults and could halve the dose interval for booster jabs from six to three months in a bid to accelerate its vaccination programme amid concern over the new Omicron coronavirus variant, as number of new cases found in the country rise.
The move, backed by a scientific advisory body and Health Secretary Sajid Javid, comes as ministers scramble to react swiftly to the new variant, which was first detected in South Africa.
Prime minister Boris Johnson has responded to the emergence of Omicron by making mask-wearing compulsory in shops and on public transport in England.
Until now, only adults in the UK aged 40 and above were eligible for a booster dose six months after their last.
But that timeframe will now be halved to three months, alongside the programme's expansion to all over-18s, with priority given to older people.
"These measures will protect more people, more quickly and make us better protected as a nation," Javid told MPs.
Has the government in England learned nothing from the Covid-19 pandemic? Nigel Swift, Managing Director of Rowlands Pharmacy, part of Numark, the UK's
largest pharmacy membership association, asks reflecting on the disorderly launch of this year's flu and Covid booster vaccination program as evidence to the
contrary.
"Community pharmacies play a crucial role in ensuring eligible individuals can easily access their free NHS flu and Covid vaccinations," Swift said, adding that
delivering this essential service necessitates pharmacy staff allocating time for preparation and appointment scheduling.
"Just a few weeks ago, NHSE informed us that the vaccination program would be postponed until October, prompting pharmacies to plan accordingly and notify
patients," he said. "However, NHSE has now reversed its decision and set the program to commence on Sept. 11. Pharmacy recommended an earlier start, but NHSE opted
for a delay instead, resulting in avoidable problems."
On Aug. 30, NHSE announced plans to move up the start of the autumn vaccination drive in England to September 11, deviating from the initial October schedule,
citing concerns about a new Covid-19 variant.
Existing Covid-19 inoculations will struggle against the fast-spreading Omicron variant, the head of vaccine manufacturer Moderna warned on Tuesday (November 30), as countries ramp up vaccination programmes and impose further restrictions in an effort to curb growing concern.
First reported to the World Health Organization in South Africa less than a week ago, the new strain has rapidly spread from Africa to the Pacific, and from Europe
to North America as dozens of countries have announced travel restrictions.
While no deaths have yet been reported from Omicron, and it could take weeks to know how infectious and how resistant the strain may prove to vaccines, its emergence underscores how besieged the world remains by Covid-19, nearly two years after the first cases were recorded.
Stephane Bancel, the head of US vaccine manufacturer Moderna, told the Financial Times in an interview published today that data would be available on the effectiveness of vaccines in the two weeks' time, but that scientists were pessimistic.
With growing concerns over the spread of Omicron variant, the UK has signed two contracts with drug majors Pfizer Inc. and Merck & Co to buy 4.25 million courses of antivirals for the NHS patients.
The move is aimed at reducing hospitalisations and easing pressures on the NHS.
The two new contracts are for 1.75 million additional courses of Merck Sharp and Dohme's (MSD) molnupiravir (Lagevrio®) and 2.5 million additional courses of PF-07321332/ritonavir (Paxlovid™) from Pfizer.
The ordered drugs will be available from early next year and both are expected to be effective against Omicron.
The recent order is in addition to the 480,000 courses of molnupiravir and 250,000 courses of PF-07321332/ritonavir procurement announced in October.